Obesity in dose calculation: A mouse or an elephant?

Journal of Clinical Oncology

Volumn 25, Issue 30, 2007, Pages 4703-4704

  Gurney, Howard ^a   Shaw, Rachel ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; RITONAVIR; ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; BODY MASS; BODY SIZE; BODY SURFACE; BODY WEIGHT; BREAST CANCER; CANCER CHEMOTHERAPY; DOSE CALCULATION; DRUG CLEARANCE; EDITORIAL; HIGH RISK PATIENT; HUMAN; LEAN BODY WEIGHT; MEASUREMENT; OBESITY; PARAMETER; PRIORITY JOURNAL; METABOLIC CLEARANCE RATE; METABOLISM; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; BODY SIZE; BODY SURFACE AREA; BODY WEIGHT; HUMANS; METABOLIC CLEARANCE RATE; OBESITY;

EID: 36048960043     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.1078     Document Type: Editorial

References (14)

1. Griggs J, Culakova E, Sorbero MES, et al: Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol 25:277-284, 2007
2. Griggs J, Sorbero MES, Lyman GH: Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 165:1267-1273, 2005
3. Jenkins P, Elyan S, Freeman S: Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. Eur J Cancer 43:544-548, 2007
4. Rosner GL, Hargis JB, Hollis DR, et al: Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: Results from Cancer and Leukemia Group B study 8541. J Clin Oncol 14:3000-3008, 1996
5. Colleoni M, Li S, Gelber RD, et al: Relation between chemotherapy dose, oestrogen receptor expression and body-mass index. Lancet 366:1108-1110, 2005
6. Sparreboom A, Wolff AC, Mathijssen RH, et al: Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25:4707-4713, 2007
7. Wong M, Balleine RL, Blair EY, et al: Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol 24:2448-2455, 2006
8. Ramchandani RP, Wang Y, Booth BP, et al: The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 47:78-86, 2007
9. Morel A, Boisdron-Celle M, Fey L, et al: Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 5:2895-2904, 2006
10. Bower M, McCall-Peat N, Ryan N, et al: Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 104:2943-2946, 2004
11. Gurney H: Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J Clin Oncol 14:2590-2611, 1996
12. Bergh J, Wiklund T, Erikstein B, et al: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomized trial. Lancet 356:1384-1391, 2000
13. Gurney H: I don't underdose my patients, Do I? Lancet Oncol 6:637-638, 2005
14. Bénézet S, Guimbaud R, Chatelut E, et al: How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients. Ann Oncol 8:607-609, 1997